Compounds > 5-hydroxymethylcytosine
Page last updated: 2024-08-25

5-hydroxymethylcytosine and Recrudescence

5-hydroxymethylcytosine has been researched along with Recrudescence in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dinulescu, DM; Getchell, CR; Gupta, M; Hasselblatt, KT; Hirsch, MS; Kaplan, SJ; Ko, JY; Lee, JJ; Li, W; Lian, CG; Liu, JF; MacDonald, LA; Malik, A; Matulonis, UA; McCarthy, ET; Medina, JE; Murphy, GF; Ohman, AW; Sasamoto, N; Shafrir, A; Terry, KL; Tucker, DW; Xu, S; Zhang, H1
Aguilar, S; Argilés, G; Arqués, O; Arroyo, AG; Caratù, G; Casanovas, O; Chicote, I; Cuesta-Borrás, E; Dienstmann, R; Eguizabal, C; Gonzalo, P; Landolfi, S; Martínez-Quintanilla, J; Nuciforo, P; Palmer, HG; Prat, A; Puig, I; Ramírez, L; Recio, JA; Seoane, J; Serra, V; Soto, A; Tabernero, J; Tenbaum, SP; Terracciano, L; Villanueva, A; Vivancos, A1
Ahn, JS; Ahn, SY; Choi, SH; Jang, JH; Jung, CW; Jung, SH; Kim, DD; Kim, HJ; Kim, SH; Kim, YK; Lee, JJ; Lee, SS; Michael, S; Minden, MD; Moon, JH; Park, HJ; Sohn, SK; Won, JH; Yang, DH1

Other Studies

3 other study(ies) available for 5-hydroxymethylcytosine and Recrudescence

ArticleYear
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 03-15, Volume: 24, Issue:6

    Topics: 5-Methylcytosine; Animals; Cell Survival; Cellular Reprogramming; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dioxygenases; Disease Models, Animal; Disease Progression; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Prognosis; Proto-Oncogene Proteins; Recurrence; Survival Analysis; Xenograft Model Antitumor Assays

2018
TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence.
    The Journal of clinical investigation, 2018, 08-31, Volume: 128, Issue:9

    Topics: 5-Methylcytosine; Animals; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Survival; Dioxygenases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Knockdown Techniques; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Proto-Oncogene Proteins; Recurrence; Xenograft Model Antitumor Assays

2018
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: 5-Methylcytosine; Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Dioxygenases; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA-Binding Proteins; Enzyme-Linked Immunosorbent Assay; Epigenesis, Genetic; Female; Genetic Predisposition to Disease; Humans; Isocitrate Dehydrogenase; Kaplan-Meier Estimate; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Phenotype; Predictive Value of Tests; Proportional Hazards Models; Proto-Oncogene Proteins; Recurrence; Time Factors; Treatment Outcome; Young Adult

2017